CorMedix Stock Soars 11% After Management Forecasts Higher Reimbursement Payments
Shares entered Monday down 60% for the year, while the company has suspended its 2027 DefenCath sales outlook.
CorMedix, which develops and sells treatments for life-threatening conditions, soared 10.7% to $5.16 in Monday trading, as of 9:52 AM ET, adding $40 million in market value. The rebound followed management's forecast of higher reimbursement payments in a Friday SEC filing, even with customer pricing and usage still unsettled.
Higher Payments, Deferred Sales Outlook
Management expects the average 2027 reimbursement add-on to be at least double the $2.37 baseline, but below the $8.32 first-quarter payment. It expects every quarter's payment to exceed $2.37.
CorMedix has suspended its outlook for 2027 DefenCath sales until it can better assess utilization, customer pricing and Medicare Advantage contracting. Its Thursday earnings release attributed that decision to changes in the Medicare reimbursement framework.
DefenCath is a solution used in catheters to reduce bloodstream infections in adults receiving chronic hemodialysis for kidney failure. It is CorMedix's largest net-sales contributor, sold mainly to outpatient dialysis clinics and hospitals. The company believes its contracted dialysis customers cover roughly 60% of U.S. outpatient dialysis centers.
A Rebound From A Steep Slide
CorMedix was on pace Monday for its biggest one-day gain since Aug. 13, with a market value of about $410 million. At Friday's close, shares were down 60% for the year, against an 11% S&P 500 gain, and had fallen 37% over the previous month.
Third-quarter revenue was $54.5 million, with a $14.7 million net loss and a loss per share of $0.19. Adjusted earnings before interest, taxes, depreciation and amortization were $3.1 million.
DefenCath contributed $17.2 million of net revenue, including a favorable $5 million adjustment to estimated sales allowances. CorMedix said large outpatient customers largely maintained usage despite reimbursement changes that affected pricing. Other products and grant income contributed $37.3 million.
The company kept its annual revenue forecast at $325 million–$345 million. It narrowed adjusted earnings guidance to $130 million–$140 million from $125 million–$140 million, and cut expected cash operating expenses to $140 million–$145 million from $145 million–$155 million. Cash and short-term investments, excluding restricted cash, totaled $355.2 million at September 30.
Heron Would Expand The Product Portfolio
CorMedix agreed on November 9 to buy substantially all of Heron Therapeutics' assets, with closing anticipated in the first quarter of 2027. The four commercial products would build on a portfolio expanded by its August 29, 2025 purchase of Melinta Therapeutics, which added six infectious-disease products, including REZZAYO, MINOCIN IV and VABOMERE, plus cardiovascular drug TOPROL-XL.
Joseph Todisco, CorMedix's chairman and chief executive officer, said in the Thursday release: “we expect the Heron transaction to effectively double the Company’s non-DefenCath annual product revenue.” He anticipates $125 million–$150 million in full-year 2027 revenue from the assets and expects the purchase to add immediately to earnings and free cash flow upon closing, according to the earnings release.
CorMedix arranged a term loan of up to $150 million and expects to draw $75 million at closing. It also expects first-quarter 2027 FDA action on a priority-review application to expand REZZAYO's use to preventing invasive fungal disease, developed with partner Mundipharma. If approved, management plans promotional efforts in the second half of 2027.
CorMedix expects to revisit DefenCath sales guidance in early 2027, when it anticipates a clearer picture of usage, pricing and Medicare Advantage contracting.
Sources
- CorMedix Inc. (NasdaqGM:CRMD) : Cases :: Law360 — law360.com
- The company's filing (CorMedix) — SEC filing
- CorMedix — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
- CorMedix — earnings release (Form 8-K, Item 2.02), filed 2026-11-12 — SEC EDGAR